La start-up TheraSonic lève ses premiers fonds
法国初创公司TheraSonic近日宣布完成100万欧元首轮融资。该公司成立于2023年底，源自法国原子能和替代能源委员会（CEA），致力于开发一种通过聚焦超声波向大脑递送药物的创新技术。
此次融资将主要用于推进其技术的首次临床试验。该技术的核心是利用聚焦超声波非侵入性地打开血脑屏障，从而将药物精准输送到大脑特定区域，为治疗阿尔茨海默病、帕金森病等神经系统疾病提供了新途径。
作为CEA的衍生企业，TheraSonic的技术基础源于该机构在医学超声领域多年的研究成果。此次成功融资标志着该技术从实验室向临床转化迈出了关键一步。
French biotech startup TheraSonic has secured €1 million in its first funding round. Founded in late 2023 as a spin-off from the French Alternative Energies and Atomic Energy Commission (CEA), the company will use the capital to conduct the first clinical trial of its novel drug delivery technology.
TheraSonic's platform uses focused ultrasound to non-invasively deliver therapeutic drugs across the blood-brain barrier, a significant challenge in treating neurological diseases. This initial funding is aimed at translating the laboratory-proven concept into a clinical reality, paving the way for potential new treatments for conditions like brain tumors and neurodegenerative disorders.
Créée fin 2023 et issue du CEA, la start-up TheraSonic annonce une levée de fonds d’1 million d’euros. Objectif : concrétiser le premier essai clinique de sa technologie qui permet de délivrer dans le cerveau des médicaments grâce à l'utilisation d'ultrasons focalisés.
TheraSonic, a CEA spinout founded in late 2023, raised €1 million to advance its first clinical trial for ultrasound-based drug delivery into the brain.
TheraSonic — medical technology start-up, based in France.
CEA — French public research organization, based in France.
Monitor — early-stage medtech funding with clinical-trial potential, but limited immediate market impact.